BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Drug Development

  AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase II Portion of the TiNivo Study in Renal Cell Carcinoma

  The results were presented today at the 2018 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), in a poster presentation titled “Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC)” (Abstract 618).

  February 10, 2018

   · 

  9 min read
• iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference

  iTeos Therapeutics today announces that it will present new data for its A2A antagonist and anti-TIGIT antibody programs.

  February 10, 2018

   · 

  6 min read
• Net Scientific: Publication in Nature Scientific Reports Describes Potential of Vortex Technology in Personalised Medicine for Lung Cancer Patients

  NetScientific notes that its portfolio company, Vortex Technology, has announced a report published by Nature Scientific Reports.

  February 10, 2018

   · 

  1 min read
• Business

  BioSciencesCorp Partners With Mab-Venture on Biosimilar Development for Emerging Markets including but not limited to India, SAARC, MENA, Turkey, LatAm, Russia

  Through Mab-Venture’s strict adherence to ICH guidelines and global development expertise, they will manufacture these programs in support of global clinical trials.

  February 10, 2018

   · 

  4 min read